AbbVie will use the Oxford site to advance treatments for immunological, neurological and oncological diseases.

Experts note that Democrats are likely to place Trump’s MFN deals under the microscope and vie to reverse sweeping Medicaid cuts following the midterm results.

GEBRO Holding and Spektus Pharma have agreed a global commercialisation partnership for ActraFlex, an extended-release pain management therapy taken twice daily.

Combining longitudinal claims data with deeper inpatient detail supports stronger real-world evidence for life sciences and medical device research.

The FDA has accepted a BLA under its accelerated approval pathway from uniQure for ifezuntirgene inilparvovec to treat Huntington’s disease.

Inovio has secured accelerated approval from the FDA for Voceryq to minimise the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP).

The policy will allow licensed professionals to use certain wellness-focused peptides not approved by the FDA in their compounded medicines.

Fresenius and WuXi Biologics will work together to develop up to 37 biosimilar candidates targeting a range of therapeutic areas, giving the German company ample scope to bolster ...

Pelthos Therapeutics has agreed to merge with Castle Creek Biosciences to form a new biotechnology company that will focus on serious diseases affecting the skin.

Xtandi's label as the cancer treatment paradigm shifts towards the use of mutation-specific targeted therapies.

Anthropic hopes Powerful AI will “match or exceed the cognitive capabilities of top human experts across scientific disciplines”.

Reaction from the life sciences industry to the Autumn Budget was mixed, with the government opting for a more macro focus on business scaling.